Premium
Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?
Author(s) -
Kirby Roger S.,
Carson Culley,
Dasgupta Prokar
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12681
Subject(s) - medicine , chapel , original research , library science , art history , art , computer science
There is in fact a very reasonable rationale for the use of a long-acting phosphodiesterase type 5 (PDE5) inhibitor in the treatment of men with symptoms of abacterial prostatitis/prostatodynia. The underlying cause of these symptoms has long been a source of speculation. In the absence of an identifiable infective agent, the current widespread use of antibiotics as a treatment option defies logic. Over 30 years ago, Kirby et al. [1] suggested that intraprostatic reflux of urine might be an important initiating factor. In 2007, Grimsley et al. [2] suggested that PDE5 inhibitors might relax the smooth muscle in the prostatic ducts and thereby have a role in the management of prostatitis, but provided no evidence for the hypothesis.